Certain baseline characteristics appear to show greater epidermal growth factor receptor (EGFR) mutations in patients with advanced non-small-cell lung cancer (NSCLC), according to a recent study published online in the journal Cancer Epidemiology, Biomarkers and Prevention.

The REASON trial, an observational, non-interventional multicenter study, evaluated Caucasian patients with advanced NSCLC in Germany.

A total of 4,196 patients met the inclusion criteria: age greater than or equal to 18, stage IIIb/IV NSCLC, EGFR mutation testing and first-line systemic treatment candidates, and surgery or radiotherapy ineligible patients.

The primary endpoint was the correlation of mutation status with baseline characteristics, with first-line treatment decision as the secondary endpoint.

Results showed that of 431 patients who had EGFR mutations, females (OR= 1.85; 95% CI: 1.48, 2.32) with adenocarcinoma (OR= 2.94; 95% CI: 2.17, 4.08) who had never smoked (OR= 3.64; 95% CI: 2.91, 4.56) showed correlation with EGFR mutation status (P <0.0001).

The most common first-line systemic treatments used were combination chemotherapy in EGFR mutation-negative NSCLC (78.5%), and EGFR-TKIs in EGFR mutation-positive NSCLC (56.6%).

RELATED: Cisplatin-Based Doublet May Improve Survival in Relapsed Lung Cancer

The findings suggest that in Caucasian patients who are females with adenocarcinoma histology, and non-smokers showed more likelihood of having EGFR mutations.

The study further proposed that these findings ultimately could help clinical decisions in advanced NSCLC by understanding its prognostic and predictive factors.

Reference